LP
ATOS icon

LMR Partners’s Atossa Therapeutics ATOS Stock Holding History

LMR Partners’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,782
Closed -$35K – 1114
2022
Q3 		$35K Hold
2,782
– – ﹤0.01% 1129
2022
Q2 		$45K Buy
+2,782
New +$43.8K ﹤0.01% 1169
2021
Q2 		– Sell
-1,288
Closed -$41K – 1118
2021
Q1 		$41K Buy
+1,288
New +$47.1K ﹤0.01% 918

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

LMR Partners's ATOS Position: Q4 2022 in Review

LMR Partners sold out of Atossa Therapeutics (ATOS) in Q4 2022, closing a stake of 2,782 shares — an estimated $35K sold.

LMR Partners first reported a position in ATOS in Q1 2021 and held it in 3 quarters. The position peaked at $45K in Q2 2022. 51 funds tracked by Wall St. Rank hold ATOS as of Q4 2022.

  • LMR Partners reported no remaining Atossa Therapeutics position as of Q4 2022 after selling out during the quarter.
  • LMR Partners sold 2,782 Atossa Therapeutics shares in Q4 2022, an estimated $35K.
  • LMR Partners first reported a position in Atossa Therapeutics in Q1 2021 and held it in 3 quarters.
  • LMR Partners's Atossa Therapeutics position peaked at $45K in Q2 2022.
  • 51 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.